Dr. Diamond is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1635 Aurora Ct
Aurora, CO 80045Phone+1 720-848-0000Fax+1 720-848-6802- Is this information wrong?
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2007 - 2010- University of ColoradoResidency, Internal Medicine, 2004 - 2007
University of Arizona College of MedicineClass of 2004
Certifications & Licensure
CO State Medical License 2007 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC Start of enrollment: 2012 Jul 01
- ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors Start of enrollment: 2014 Apr 01
- A Study of OKI-179 in Patients With Solid Tumors Start of enrollment: 2019 May 08
- Join now to see all
Publications & Presentations
PubMed
- Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.Stephen G Smoots, Anna R Schreiber, Marilyn M Jackson, Stacey M Bagby, Adrian T A Dominguez, Evan D Dus, Cameron A Binns, Morgan MacBeth, Phaedra A Whitty, Jennifer R ...> ;Breast Cancer Research. 2024 Mar 1
- First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.Schreiber, A., Kagihara, J., Corr, B., Davis, S., Lieu, C., Kim, S., Jimeno, A., Camidge, D., Williams, J., Heim, A., Martin, A., DeMattei, J., Holay, N., Triplett, T....> ;Cancers. 2023 Dec 23
- 1 citationsSafety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.Elena Shagisultanova, William Gradishar, Pavani Chalasani, Andrew J Brenner, Alison Stopeck, Hannah Parris, Dexiang Gao, Jose Mayordomo, Peter Kabos, Virginia F Borges...> ;Clinical Cancer Research. 2023 Dec 15
- Join now to see all
Press Mentions
OnKure Therapeutics Appoints Jennifer R. Diamond, M.D., as Chief Medical OfficerOctober 14th, 2021- Increase in Cancer Deaths Predicted Due to COVID-19 PandemicDecember 22nd, 2020
OnKure and CU Cancer Center Announce First Patient Enrolled in Clinical Trial of OKI-179, a Potent and Selective HDAC InhibitorJune 17th, 2019- Join now to see all
Hospital Affiliations
University of Colorado HospitalAurora, Colorado
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
